• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Subcutaneous risankizumab maintenance therapy superior to placebo for moderate-severe Crohn’s disease

byJessie WillisandTeddy Guo
June 8, 2022
in Chronic Disease, Gastroenterology, Rheumatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Compared to a placebo (withdrawal) group, patients maintained on subcutaneous risankizumab had greater rates of clinical remission.

2. Adverse events were similar between the treatment and placebo group with worsening of Crohn’s disease and nasopharyngitis being the most common adverse events.

Evidence Rating Level: 1 (Excellent)

Study Rundown: This study is a follow-up to the ADVANCE and MOTIVATE phase 3 drug trials. During the prior trials, participants received induction therapy with IV risankizumab or placebo for moderately to severely active Crohn’s disease. These studies aimed to evaluate the efficacy of induction risankizumab for up to 12 weeks. However, long-term efficacy data on risankizumab is limited. The aim of this FORTIFY trial was to evaluate the efficacy of maintenance therapy with subcutaneous risankizumab for patients who experienced benefit from the initial IV induction therapy. Participants were randomized 1:1:1 to either withdrawal (placebo), 180 mg or 360 mg subcutaneous risankizumab every eight weeks for up to 52 weeks. Subcutaneous risankizumab was well tolerated, with no significant difference in adverse event rates between the treatment versus withdrawal group. Remission was evaluated clinically, by Crohn’s disease activity index (CDAI) score and endoscopically. Greater remission was seen in both the 180 mg and 360 mg risankizumab group compared to the withdrawal group. Limitations of this study include the potential long half-life of risankizumab which would have necessitated longer study duration. Nonetheless, this study demonstrated clinical remission with patients on subcutaneous risankizumab maintenance therapy compared to the withdrawal group.

Click to read the study in The Lancet

Relevant Reading: IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease

In-Depth [randomized control trial]: The FORTIFY randomized control trial is a phase 3 withdrawal study of subcutaneous risankizumab. Eligibility criteria included previous clinical response in the ADVANCE and MOTIVATE intravenous risankizumab trial. Patients were aged 16-80 years old with Crohn’s disease graded as moderately or severely active by CDAI 220-450. Participants were randomized 1:1:1 to either placebo/withdrawal (n=164), 180 mg (n=157) or 360 mg risankizumab (n=141) every 8 weeks. Primary outcomes were evaluated at week 52. Clinical remission was evaluated on the CDAI scale and endoscopically. Greater clinical remission was reached with the 360 mg group compared to placebo by CDAI score (52% vs 41%, adjusted difference 15%). Clinically, stool frequency and abdominal pain were also greater in the 360 mg group compared to placebo (52% vs 40%, adjusted difference 15%). This was the same for endoscopic remission (47% vs. 22%, adjusted difference 28%). For the 180 mg group, CDAI remission was reached in 55% patients and endoscopic remission in 47% of patients. Adverse events were not significantly different between groups. The most frequently reported adverse events were worsening Crohn’s, nasopharyngitis, and arthralgia. These were experienced most frequently in the withdrawal group.

RELATED REPORTS

Risk of hydroxychloroquine retinopathy increases with longer use and higher dosage

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: biologicsCrohn's DiseaseGastroenterologyinflammatory bowel diseaseinflammatory bowel disease (IBD)rheumatologyrisankizumab
Previous Post

Sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization in type 2 diabetes patients

Next Post

Wellness Check: Exercise

RelatedReports

Blindness and visual impairment decreasing worldwide
Chronic Disease

Risk of hydroxychloroquine retinopathy increases with longer use and higher dosage

February 1, 2023
Resection of colorectal liver metastases may improve cost and longevity
Chronic Disease

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

January 30, 2023
Long-term use of apremilast for psoriasis associated with an acceptable safety profile
Chronic Disease

Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults

January 24, 2023
Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs
Chronic Disease

Early-life body size not an independent risk factor for colorectal cancer

January 11, 2023
Next Post
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

Wellness Check: Exercise

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

The VICTORIA trial: Transcatheter aortic-valve replacement versus surgery [Classics Series]

Patient Basics: Kidney Transplant

Perioperative dexmedetomidine decreases the incidence of select complications following kidney transplantation

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
  • High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options